Friday, 8 December 2017

Enteric Disease Testing to Alleviate Mortality among Humans

Increasing presence of pathogens in the air and rising number of casualties have increased the requirement of timely enteric disease testing in humans. Enteric diseases, resulting in symptoms such as nausea, diarrhea, and vomiting, generally happen due to consumption of contaminated food or water. Such diseases are highly communicable and timely testing can help doctors diagnose the accurate problem and provide early treatment. 

Rising Strategic Initiatives from Healthcare Organizations

Generally, there are three different types of enteric diseases: bacterial, viral, and parasitic. In 2016, enteric diseases caused by bacteria dominated the market. Salmonella, C. difficile, Shigella, E. coli, and Campylobacter are few bacteria that can cause enteric diseases. Increasing dependency on fast food and insufficient health awareness among humans is giving rise to bacterial infections. According to World Health Organization (WHO), around 1,72,454 people across the world get infected by cholera, resulting in high mortality rate. To handle the situation, various institutes and organizations in healthcare are taking strategic initiatives by promoting timely testing for such infections through healthcare camps and improving vaccines. For instance, a team of researchers at the University of Buffalo in New York is developing a new vaccine that will eradicate maximum bacteria strains causing pneumonia. Current versions of the vaccine can eradicate only 23 forms of Streptococcus pneumonia, including sepsis and meningitis. This advanced vaccine, on the other hand, can handle 72 forms of bacteria out of 90. 

Market Insights

Growing number of molecular diagnostic centers and advanced diagnostic technologies are expected to boost the global enteric disease testing market. In addition, rising dependency of humans on unhygienic fast food and increasing cases of mortality due to enteric infections can augment market growth. Frequent strategic initiatives taken by various healthcare organizations are likely to help the market reach a value of USD 4.2 billion by 2025, states Grand View Research Inc. in a recent report.

Some of the prominent players in the market are Alere Inc.; Quest Diagnostics; Bio Rad Laboratories; Becton Dickinson and Company; and Cepheid.

To get free sample request at:

No comments: